Terms: = Pancreatic cancer AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS AND Prognosis
10 results:
1. EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway.
Wang Y; Qin C; Zhao B; Li Z; Li T; Yang X; Zhao Y; Wang W
J Transl Med; 2023 Mar; 21(1):201. PubMed ID: 36932397
[TBL] [Abstract] [Full Text] [Related]
2. Establishment and Molecular Characterization of Two Patient-Derived pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response.
Braun R; Lapshyna O; Watzelt J; Drenckhan M; Künstner A; Färber B; Hael AAM; Bolm L; Honselmann KC; Konukiewitz B; Castven D; Spielmann M; Gorantla SP; Busch H; Marquardt JU; Keck T; Wellner UF; Ungefroren H
Cells; 2023 Feb; 12(4):. PubMed ID: 36831254
[TBL] [Abstract] [Full Text] [Related]
3. Blood-Based Diagnosis and Risk Stratification of Patients with pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN).
Zhang C; Al-Shaheri FN; Alhamdani MSS; Bauer AS; Hoheisel JD; Schenk M; Hinz U; Goedecke P; Al-Halabi K; Büchler MW; Giese NA; Hackert T; Roth S
Clin Cancer Res; 2023 Apr; 29(8):1535-1545. PubMed ID: 36516200
[TBL] [Abstract] [Full Text] [Related]
4. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer.
Ono H; Kato T; Murase Y; Nakamura Y; Ishikawa Y; Watanabe S; Akahoshi K; Ogura T; Ogawa K; Ban D; Kudo A; Akiyama Y; Tanaka S; Ito H; Tanabe M
Sci Rep; 2021 May; 11(1):10078. PubMed ID: 33980911
[TBL] [Abstract] [Full Text] [Related]
5. Methylation-mediated LINC00261 suppresses pancreatic cancer progression by epigenetically inhibiting c-Myc transcription.
Liu S; Zheng Y; Zhang Y; Zhang J; Xie F; Guo S; Gu J; Yang J; Zheng P; Lai J; Yin L; Wang H
Theranostics; 2020; 10(23):10634-10651. PubMed ID: 32929371
[No Abstract] [Full Text] [Related]
6. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer.
Zheng Y; Wu C; Yang J; Zhao Y; Jia H; Xue M; Xu D; Yang F; Fu D; Wang C; Hu B; Zhang Z; Li T; Yan S; Wang X; Nelson PJ; Bruns C; Qin L; Dong Q
Signal Transduct Target Ther; 2020 May; 5(1):53. PubMed ID: 32398667
[TBL] [Abstract] [Full Text] [Related]
7. A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma.
Huang H; Zou Y; Zhang H; Li X; Li Y; Deng X; Sun H; Guo Z; Ao L
Transl Res; 2020 May; 219():30-44. PubMed ID: 32119844
[TBL] [Abstract] [Full Text] [Related]
8. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.
Pusceddu S; Barretta F; Trama A; Botta L; Milione M; Buzzoni R; De Braud F; Mazzaferro V; Pastorino U; Seregni E; Mariani L; Gatta G; Di Bartolomeo M; Femia D; Prinzi N; Coppa J; Panzuto F; Antonuzzo L; Bajetta E; Brizzi MP; Campana D; Catena L; Comber H; Dwane F; Fazio N; Faggiano A; Giuffrida D; Henau K; Ibrahim T; Marconcini R; Massironi S; Žakelj MP; Spada F; Tafuto S; Van Eycken E; Van der Zwan JM; Žagar T; Giacomelli L; Miceli R;
Endocr Relat Cancer; 2018 Jun; 25(6):607-618. PubMed ID: 29559553
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathological significance of cell cycle regulatory factors and differentiation-related factors in pancreatic neoplasms.
Kamio Y; Maeda K; Moriya T; Takasu N; Takeshita A; Hirai I; Kimura W; Yamakawa M
Pancreas; 2010 Apr; 39(3):345-52. PubMed ID: 20335778
[TBL] [Abstract] [Full Text] [Related]
10. [Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer].
Zhou JX; Hong GB; Xu LY; Xu LF; Chen YT; Jiang RJ; Luo JH
Ai Zheng; 2004 Dec; 23(12):1677-80. PubMed ID: 15601559
[TBL] [Abstract] [Full Text] [Related]
